CYP46A1 and early-onset autosomal dominant Alzheimer disease: Mast at al. have proposed CYP46A1 as a pharmacological target for Alzheimer’s disease (AD) [45], while Burlot et al. have shown that adeno-associated virus (AAV) delivery of CYP46A1 to an AD mouse model rescued cognitive defects associated with the model [46].